Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone

International Journal of Psychiatry in Clinical Practice

Volumn 16, Issue 2, 2012, Pages 153-156

  Letmaier, Martin ^a   Painold, Annamaria ^a   Holl, Anna Katharina ^a   Grohmann, Renate ^b   Vergin, Hartmut ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Adverse drug reaction; Aripiprazole; Pharmacodynamics; Psychosis; Schizoaffective disorder

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE; RISPERIDONE; VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; HUMAN; LABORATORY TEST; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HALOPERIDOL; HUMANS; PIPERAZINES; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; QUINOLONES; RECURRENCE; RISPERIDONE;

EID: 84860849482     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.644300     Document Type: Article

References (20)

1. Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affi nity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-9
2. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681-90
3. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebocontrolled trials. Schizophr Res 2003;61(2 - 3):123-36
4. Ahuja N, Lloyd AJ. Worsening of psychosis in a 30 year old man with undifferentiated schizophrenia. Ann Clin Psychiatry 2008;20(2):113-4
5. Barnas ME, Hussain N, Petrides G. Treatment-emergent psychosis with aripiprazole. J Clin Psychiatry 2005;66(10):1339
6. Burke MJ, Lincoln J. Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. Ann Clin Psychiatry 2006;18(2):129-30
7. Glick ID, Duggal V, Hodulik C. Aripiprazole as a dopamine partial agonist: positive and negative effects. J Clin Psychopharmacol. 2006;26(1):101-3
8. Kapusta ND, Mossaheb N, Barnas C, Fischer P. Aripiprazole- induced psychosis: a case report of reexposure by stepwise up-titration. J Clin Psychiatry 2007;68(9): 1445-6
9. Ramaswamy S, Vijay D, William M, Sattar SP, Praveen F, Petty F. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004;19(1):45-8
10. Reeves RR, Mack JE. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 2004;161(7):1308
11. Grohmann R, Engel RR, Ruther E, Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004;37(Suppl 1):S4 - 11
12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-76
14. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164(9): 1404-10
15. U zun S, Kozumplik O, Mimica N, Folnegovic-Smalc V. Aripiprazole: an overview of a novel antipsychotic. Psychiatr Danub 2005;17(1 - 2):67-75
16. Kuo J, Hwu HG. Aripiprazole and haloperidol: benefi cial combination antipsychotic therapy for a schizophrenic patient. Clin Neuropharmacol 2008;31(3):173-5
17. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berlin) 2000;152(2):174-80
18. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double- blind, placebo-controlled trial. J Clin Psychiatry 2008;69(5):720-31
19. Grohmann R, Strobel C, Ruther E, Dirschedl P, Helmchen H, Hippius H, et al. Adverse psychic reactions to psychotropic drugs - a report from the AMUP study. Pharmacopsychiatry 1993;26(3):84-93
20. Adan-Manes J, Garcia-Parajua P. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J Clin Pharm Ther 2009;34(2):245-6